Company |
Partner |
Amount (US$M) |
Details |
Date |
Total: $41.07M (Year-to-date: $756.55M) | ||||
Basilea Pharmaceutica Ltd. (Basel, Switzerland) |
Astellas Pharma Inc. (Tokyo) |
$5.07 |
U.S. sales of Cresemba (isavuconazole), an antifungal treatment, have triggered the first sales milestone payment from Astellas; Basilea is due to receive CHF5M (US5.07M) |
10/24/17 |
Cadent Therapeutics Inc. (Cambridge, Mass.) |
Novartis AG (Basel, Switzerland) |
ND |
Following the start of a phase I trial concerning a subtype selective NMDA receptive negative allosteric modulator (NAM) to treat treatment-resistant depression; Novartis has obtained an exclusive IP license from Cadent for various compounds that selectively modulate NR2B-containing NMDA receptors |
10/18/17 |
Evotec AG (Hamburg, Germany) |
Celgene Corp. (Summit, N.J.) |
$5.00 |
For the successful completion of a screening campaign using Evotec's induced pluripotent stem cell-based screening platform |
10/11/17 |
Exelixis Inc. (South San Francisco) |
Bristol-Myers Squibb Co. (New York) |
$10.00 |
For BMS' filing of a clinical trial authorization in Europe for a first-in-human study of a RORyt inverse agonist |
10/5/17 |
Fibrogen Inc. (San Francisco) |
Astrazeneca plc (London) |
$15.00 |
CFDA accepted the NDA for roxadustat (FG-4592), an oral treatment for anemia in dialysis-dependent chronic kidney disease (CKD) and nondialysis-dependent CKD patients |
10/19/17 |
Infinity Pharmaceuticals Inc. (Cambridge, Mass.) |
Verastem Inc. (Boston) |
$6.00 |
For the positive top-line results from the phase III DUO trial testing duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma |
10/18/17 |
Innovative Targeting Solutions Inc. (San Francisco) |
Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) |
ND |
Achieved its fourth milestone in its collaboration using ITS' Hutarg research platform to discover antibody candidates useful for modulating immune responses in autoimmunity or cancer |
10/12/17 |
Sutro Biopharma Inc. (South San Francisco) |
Celgene Corp. (Summit, N.J.) |
ND |
Received an undisclosed manufacturing milestone payment for completing production of STRO-001, an antibody-drug conjugate, using Sutro's cell-free protein synthesis technology; STRO-001 will be tested in clinical trials in patients with multiple myeloma and aggressive and indolent lymphomas starting in the first quarter of 2018 |
10/12/17 |
Notes Currency conversions are based on exchange rates at the time of the deal. This chart includes only biotech companies that develop therapeutics. |